Liquidia Corporation
LQDA
Rangering i aksjer
#4864
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Aksjekurs
$34.62
Markedsverdi
$3.10B
Endring (1 dag)
0.78%
Endring (1 år)
54.00%
Land
US
Handel Liquidia Corporation (LQDA)
Kategori
Healthcare
EPS for Liquidia Corporation (LQDA)
EPS per June 2026 TTM: $1.57
Ifølge de siste økonomiske rapportene og aksjekursen til Liquidia Corporation er selskapets nåværende EPS (TTM) $1.57. Ved slutten av 2023 hadde selskapet en EPS på $-1.21, en økning sammenlignet med EPS-en i 2022 som var $-0.67.
EPS-historikk for Liquidia Corporation fra 2016 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $1.57 | -194.58% |
| 2024 | $-1.66 | 37.19% |
| 2023 | $-1.21 | 80.60% |
| 2022 | $-0.67 | -4.29% |
| 2021 | $-0.70 | -60.23% |
| 2020 | $-1.76 | -29.88% |
| 2019 | $-2.51 | -66.17% |
| 2018 | $-7.42 | 118.24% |
| 2017 | $-3.40 | 82.80% |
| 2016 | $-1.86 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $2.41 | 53.50% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -66.88% |
US
|
